Clinical trial · Observational
Multiomics Tumor Evolution Model of NSCLC
A Multiomics Study of Tumor Evolution Characteristics and Prognostic Model in Early-stage Non-small Cell Lung Cancer
NCT05352035CI-TRIAL-00089154recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Prospective cohort
- description
- This cohort will enroll a total of 300 patients prospectively
Primary outcomes (2)
- measure
- Disease-free survival (DFS)
- timeFrame
- Through study completion, an average of 2 years
- description
- Time from randomization to disease recurrence or death from any cause.
- measure
- Overall survival (OS)
- timeFrame
- Through study completion, an average of 2 years
- description
- Time from randomization to death from any cause.
Secondary outcomes (1)
- measure
- Relationship between translational biomarkers and clinical outcome
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old; 2. Early-stage NSCLC patients underwent radical surgical resection; 3. Sufficient tumor tissue and blood sample for study use; 4. Available clinical-pathologic data, imaging data and follow-up date; 5. Written informed consent. Exclusion Criteria: 1. History of other malignant tumors; 2. Evidence of distant metastasis before surgery; 3. Insufficient tumor tissue or blood sample for study use; 4. Clinical-pathologic data, imaging data or follow-up date is not available; 5. Other judgments by the Investigator that the patient should not participate in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.